DRUG who can shrink up to 50 percent of brain tumors in children with the disease has been launched in the UK. Later, the doctor will be able to apply for funding from the health trust to get Votubia (everolimus).
The drug was intended for children with brain tumor growth nonganas associated with a condition called tuberous sclerosis complex (TSC).
Pills are taken once daily offers an alternative to surgery and is expected to save up to 1600 young people with tumors in the UK.
Drugs that have been granted the status of drugs for rare diseases have been shown to shrink the tumor giant cell subependymal astrocytoma (SEGA) associated with TSC.
As quoted from the Press Association on Tuesday (27 / 9), TSC is a genetic disorder that leads to malignant not tumor formed in organs, especially in the brain and kidneys. Brain tumors occur in about 20 percent of patients with TSC is causing physical and mental disabilities.
The drug was intended for children with brain tumor growth nonganas associated with a condition called tuberous sclerosis complex (TSC).
Pills are taken once daily offers an alternative to surgery and is expected to save up to 1600 young people with tumors in the UK.
Drugs that have been granted the status of drugs for rare diseases have been shown to shrink the tumor giant cell subependymal astrocytoma (SEGA) associated with TSC.
As quoted from the Press Association on Tuesday (27 / 9), TSC is a genetic disorder that leads to malignant not tumor formed in organs, especially in the brain and kidneys. Brain tumors occur in about 20 percent of patients with TSC is causing physical and mental disabilities.
Chris Kingswood, Head of Research tuberous sclerosis Association said, "Since long, there has been a licensed care needs that are useful as an alternative to invasive brain surgery. Everolimus is the first licensed product that can be offered to patients to overcome conditions that undermine their cause. The drug will be works by blocking a protein that acts as an important regulator of tumor cell growth. "
Dr Finbar O'Callaghan, consultant pediatric neurology at the University of Bristol, said: "SEGA are serious complications in TSC, accounting for most of the increased mortality seen in this condition.
"Until now, brain surgery has become the only option for treatment. The availability of pharmacological therapy is certainly becoming a major milestone and provides a treatment option in cases where surgery is difficult."
Read: Tumor-fighting Universal Vaccine Ready by 2013
